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In several years after its discovery in the placenta, the human leukocyte antigen (HLA) class
Ib protein, HLA-G, was not given much attention, nor was it assigned great importance.
As time has unraveled, HLA-G has proven to have distinctive functions and an unfore-
seen and possibly important role in reproduction. HLA-G is characterized mainly by its low
polymorphism and restricted tissue distribution in non-pathological conditions. In fact, its
expression pattern is primarily limited to extravillous cytotrophoblast cells at the maternal-
fetal interface during pregnancy. Due to low polymorphism, almost the same protein is
expressed by virtually all individuals. It is these unique features that make HLA-G differ
from its highly polymorphic HLA class Ia counterparts, the HLA-A, -B, and -C molecules.
Its function, seemingly diverse, is typically receptor-mediated, and involves interactions
with a wide range of immune cells. As the expression of HLA-G primarily is limited to
gestation, this has given rise to the hypothesis that HLA-G plays an important role in the
immunological tolerance of the fetus by the mother. In keeping with this, it might not
be surprising that polymorphisms in the HLA-G gene, and levels of HLA-G expression,
have been linked to reproductive failure and pre-eclampsia. Based on recent studies, we
speculate that HLA-G might be involved in mechanisms in reproductive immunology even
before conception because HLA-G can be detected in the genital tract and in the blood of
non-pregnant women, and is present in seminal fluid from men. In addition, HLA-G expres-
sion has been found in the pre-implanted embryo.Therefore, we propose that a combined
contribution from the mother, the father, and the embryo/fetus is likely to be important.
Furthermore, this review presents important aspects of HLA-G in relation to reproduction:
from genetics to physiological effects, from pregnancy and pregnancy complications to a
short discussion on future possible means of preventative measures and therapy.
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INTRODUCTION
The uterus and the placenta constitute a unique site of immune
modulation where the semi-allogeneic fetus is tolerated by the
maternal immune system. Both the mother and the fetus con-
tribute to maintenance of tolerance. The mother through the
presence of local regulatory immune cells that regulate redun-
dant immune responses and the fetus, possibly among several
mechanisms, through expression of non-classical human major
histocompatibility complex (MHC) class Ib molecules, human
leukocyte antigen (HLA)-E, -F, and -G, on extravillous trophoblast
cells that infiltrate the decidua and make a direct contact with
maternal immune cells (1–3). To the best of our knowledge, a
classical antigen-presenting function, or capacity, of HLA-G has
never been described, although the HLA-G molecule can bind
peptides (4).
The expression of HLA-G is primarily limited to gestation and
it has been widely studied in pregnancy because of its associa-
tion with pregnancy complications, in particular pre-eclampsia
and recurrent miscarriages (2, 5–8). The expression of HLA-G by
embryos, as well as in the presence of soluble HLA-G (sHLA-G) in
the maternal circulation, is associated with better pregnancy rates
(9, 10). Furthermore, a different, possible role of HLA-G has been
proposed in the context of remodeling of spiral arteries during
placental development (11). However, further studies are needed
to confirm this.
An accumulating body of evidence suggests that HLA-G may
be an important factor in reproduction even before conception.
sHLA-G circulates in the blood of non-pregnant women (and
in the blood of male donors), HLA-G is expressed in the female
genital tract, and sHLA-G has been identified in seminal plasma
(Figure 1) (12–16). In addition, HLA-G expression has been found
in the pre-implanted embryo. Thereby, a combined contribution
from the mother, the father, and the embryo, or fetus, is likely
to be important. The aim of the present review is to give an
overview of, and to discuss, important aspects of HLA-G in rela-
tion to reproduction: from genetics to physiological effects, from
pregnancy and pregnancy complications to a short discussion on
future possible means of preventative measures and therapy.
THE HLA-G GENE
HLA-G POLYMORPHISMS IN CODING REGIONS
The HLA-G gene contains eight exons and seven introns
(Figure 2). The external part of the HLA-G molecule consists of
three parts, the α1, α2, and α3 domains (exons 2–4). The HLA-G
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The mother
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other immuno-active factors
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FIGURE 1 | An important and central role of HLA-G in reproduction may
be depicted from its wide distribution within the reproductive cycle.
HLA-G is expressed in maternal blood, in follicular fluid, and in seminal plasma
prior to implantation, and after fertilization in the blastocyst/embryo and in the
placenta by the trophoblast cells. The continuous expression of HLA-G in the
reproductive cycle may in particular modulate local immune cells in the
female reproductive system for immunological acceptance of the
semi-allogenic embryo.
The Human Leukocyte Antigen-G gene
5’-upstream regulatory region (5’URR)
3’-untranslated region (3’UTR, exon 8) 
Intron 4
Exon 1
-725 SNP
Polymorphisms influence 
HLA-G expression
Three soluble HLA-G molecules: 
• HLA-G5 (includes 21 amino acids encoded by intron 4)
• HLA-G6 (minus exon 3; includes 21 amino acids, intron 4)
• Soluble HLA-G1 (shed membrane-bound HLA-G1)
ATTTA
14 bp ins/del
+3187 SNP  +3196 SNP
+3142 SNP
Influences HLA-G alternative splicing 
and HLA-G expression levels
Seven HLA-G isoforms: 
• HLA-G1 
• HLA-G2 (exon 3 spliced out)
• HLA-G3 (minus exons 3 + 4 )
• HLA-G4 (minus exon 4)
• HLA-G5 (retains intron 4)
• HLA-G6 (minus exon 3, retains inron 4)
• HLA-G7 (retains intron 2)
FIGURE 2 | A schematic representation of the HLA-G gene. Some of the most intensively studied gene polymorphisms in the 5′-upstream regulatory region
and in the 3′-untranslated region. An overview of the different HLA-G isoforms is included.
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full-length membrane protein is anchored in the cell membrane
by the transmembrane region (exon 5). The cytoplasmic domain
is encoded by exon 6 and the very first, short part of exon 8 (3,
17). Polymorphisms in the coding region of HLA-G are relatively
scarce but evenly distributed between exons 2, 3, and 4, as well
as in introns (6, 7, 18–20). Most polymorphisms do not alter
the protein sequence, and the ones that do, allow for a group-
ing in major allele groups: G*01:01:xx:xx, G*01:01:xx, G*01:02,
G*01:03:xx:xx, G*01:04:xx, G*01:05N (null allele), G*01:06, and
G*01:07 to G*01:18. However, polymorphisms that define these
allele groups have probably no effect on the secondary structures
of the heavy chains, and the functional relevance of this nucleotide
variability remains unclear. In total, 50 alleles and 16 allele groups
representing an amino acid substitution have been described in
the HLA-G gene sequence [WHO Nomenclature Committee for
Factors of the HLA System and the International Immunogenetics
Information System (IMGT)/HLA Database].
The polymorphic deletion of the first basepair (bp) of codon
130 or the third of codon 129, which results in a frameshift, defines
the null allele (G*01:05N ), and this null allele does not encode
functional full-length HLA-G protein isoforms (HLA-G1 and -G5,
see below) (18, 21). Nonetheless, studies show that these isoforms
are not essential for fetal survival, indicating that expression of
other HLA-G isoforms or HLA-E and/or -F,which are also involved
in immune modulation in the placenta, may compensate for the
lack of HLA-G1 and -G5 protein (22–24).
HLA-G POLYMORPHISMS IN NON-CODING REGIONS
The functional mRNA level of HLA-G is governed by the rate of
synthesis, mainly driven by the promoter region, or 5′-upstream
regulatory region (5′-URR), as well as by the rate of degradation,
stability, localization,and translation of the mRNA (25) (Figure 2).
The rate at which pre-mRNA is produced is partly mediated by
pre-transcriptional events, e.g., binding of transcription factors to
regulatory motifs in the promoter region. HLA class I promot-
ers sequences are generally conserved, but the HLA-G promoter
is somewhat unique. Although its nucleotide sequence and struc-
ture is similar to other class I genes in several aspects, peculiarly,
most regulatory motifs in the HLA-G promoter region are non-
functional (20). Of importance, two main regulatory modules are
flawed. First, the interferon (IFN)/Enhancer A region is blem-
ished by a 16-bp deletion (17, 26), and second, the SXY module
that mounts the transcriptional apparatus, represents a divergent
sequence that does not allow for appropriate binding of the class
II transactivator (CIITA) (27).
The 3′-untranslated region (3′UTR) of the HLA-G gene also
exhibits several regulatory elements including AU-rich motifs and
a poly-A signal to influence mRNA stability, turnover, mobility,
and splicing pattern (20, 28). Polymorphisms in these regions may
thus affect the expression of HLA-G by altered regulation of gene
transcription or by destabilizing the mRNA transcript (28–30).
Indeed, several important polymorphisms have been described in
the 5′URR and the 3′UTR of the HLA-G gene (28, 29, 31–34).
THE 5′-UPSTREAM REGULATORY REGION OF THE HLA-G GENE
Polymorphisms in the HLA-G 5′URR are close to regulatory ele-
ments and CpG sites, and are likely to alter binding of transcription
factors and/or promoter methylation, and as a consequence influ-
ence the rate of transcription. Although sequence variation affect-
ing transcription would be expected inside regulatory elements,
most variable sites are not found in known motifs (20). Inter-
estingly, an accumulating body of evidence indicates a balancing
selection on the HLA-G promoter, and thereby indicates a prefer-
ence for heterozygosity in which, possibly, individuals with both
high- and low-expressing promoters are privileged (19, 29, 33, 35).
Few studies address the direct association between HLA-G pro-
moter SNPs and a differential HLA-G expression. One variation, a
SNP at position−725 (rs123334), is associated with sporadic mis-
carriages and differential HLA-G expression (32, 36), and others,
SNPs at position −1305,−964, and −486, are associated with yet
other conditions like vitiligo, asthma, and acute allograft rejection
in end-stage renal disease (37–39).
THE 3′ UNTRANSLATED REGION OF THE HLA-G GENE
In contrast to the coding region, the 3′UTR of the HLA-G locus
presents a rather high degree of variation. Since the 3′UTR of the
HLA-G gene exhibits several regulatory elements including AU-
rich motifs, a poly-A signal, as well as signals that regulate the
spatial and temporal expression of mRNA, the polymorphic sites
may influence mRNA stability, turnover, mobility, and splicing
pattern (20, 28, 30). A 14-bp ins/del (rs66554220) located in exon
8 is the best studied polymorphism in the 3′UTR, and has been
shown to influence HLA-G mRNA transcript size and stability (19,
28, 30, 31, 40–42). The presence of the 14-bp-insertion sequence
introduces an alternative splice site that generates a 92-bp deletion
in the 3′UTR of the HLA-G mRNAs, and this alternative splice
form seems to have an impact on the expression levels of HLA-G
(5, 28, 40, 41). The positions of polymorphism in the 3′UTR of the
HLA-G gene are in the current review numbered according to the
publication by Castelli et al., which includes the 14-bp sequence in
the reference sequence (43). At least three other SNPs in the 3′UTR
are associated with HLA-G mRNA regulation and differences in
sHLA-G levels: one positioned at+3142 (rs1063320) substituting
a C to a G, another at+3187 (rs9380142) substituting an A to a G,
and the third at position +3196 (rs1610696) where a C is substi-
tuted with a G (Figure 2). Studies show that polymorphisms in the
3′UTR probably act as targets for microRNAs, thereby controlling
HLA-G mRNA stability and expression levels (8, 43–47). Further-
more, the +3187 and the +3196 SNPs are located just before and
after an AUUUA motif associated with mRNA stability (28, 43).
COMBINED 5′URR AND 3′UTR HLA-G HAPLOTYPES
In some cases, polymorphism in the HLA-G 5′URR/promoter
region may be in linkage disequilibrium with HLA-G 3′UTR vari-
ants (19, 33, 37), and some of them might influence alternative
splicing and mRNA stability (30, 48). The−725 SNP located in the
5′URR is possibly in linkage disequilibrium with the 14-bp ins/del,
the +3142, and the +3187 polymorphic sites, and is suggested to
influence the stability of mRNA transcripts (36). Recently, the full
combinations of 5′URR haplotypes, HLA-G WHO nomenclature
alleles, and 3′UTR haplotypes in the HLA-G gene have been eluci-
dated in a Brazilian population (33). The DNA polymorphisms in
these extended HLA-G haplotypes may influence HLA-G expres-
sion and the stability of HLA-G mRNA transcripts in combination.
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Investigating the 5′URR and 3′UTR HLA-G extended haplotypes
instead of evaluating single polymorphisms could determine the
significance of allelic variants of HLA-G more accurately (33). A
study correlating 3′UTR extended haplotypes with HLA-G soluble
levels in a Brazilian and French cohort, showed that some haplo-
types were associated with high sHLA-G levels (named UTR-1)
and some with low sHLA-G levels in blood plasma from healthy
donors (named UTR-5 and UTR-7) (47). However, full consensus
does not exist in these studies, as another French study reported
conflicting results (46). These different HLA-G haplotypes differ
at the 14-bp ins/del, the +3142, the +3187, and the +3196 poly-
morphic sites in the 3′UTR, as well as in polymorphic sites in the
5′URR.
UNIQUE CHARACTERISTICS OF HLA-G
A characteristic unique to HLA-G is the post-transcriptional alter-
native splicing of the mRNA from the single HLA-G gene. HLA-G1
represents the full-length isoform, whereas the other isoforms are
formed by out-splicing of exons. This result in seven isoforms, four
of which are membrane-bound (HLA-G1, HLA-G2, HLA-G3, and
HLA-G4), and three of which are soluble (sHLA-G5, sHLA-G6,
and sHLA-G7) (40, 49, 50) (Figure 2). HLA-G1 and HLA-G5 are
the most studied isoforms. In contrast to other HLA class I genes,
exon 6 of the HLA-G gene encodes a pre-mature stop codon that
results in a truncated cytoplasmic tail (17). The truncated cytoplas-
mic tail results in a reduced endocytosis and thus a low cell surface
turnover of the HLA-G molecule (51, 52). The soluble isoforms
lack the transmembrane region due to a stop codon in intron 4
(40, 50). In the presence of metalloproteinases, HLA-G1 loaded
with peptide can be shed from the surface by proteolytic cleav-
age, also resulting in a soluble molecule. HLA-G1 and sHLA-G5
are both capable of forming heterodimers with β2-microglobulin
(β2m) (53).
HLA-G EXPRESSION AND FUNCTION IN RELATION TO
REPRODUCTION
We propose that HLA-G might be involved in mechanisms in
reproduction even before conception because HLA-G can be
detected in the genital tract and in the blood of non-pregnant
women, and is present in seminal fluid from men.
The function of HLA-G seems to be diverse, involving inter-
actions with NK cells, cytotoxic T lymphocytes, regulatory T cells
(Tregs), and it may be involved in regulating angiogenesis and cell
migration (Figure 3). HLA-G is expressed by the extravillous tro-
phoblast cells in the placenta, where the molecule has been attrib-
uted an important role in early placentation and maintenance of
successful pregnancy (2, 3). Also, HLA-G is expressed in tissues
important for the reproductive cycle. HLA-G is expressed in the
FoxP3+
Trophoblast cell
Cytotoxic CD8+ T lymphocyte (CTL)
Uterine NK cell
Regulatory T cell
CD4+ HLA-G+ T cell
HLA-G
ILT-2
HLA-G5/
sHLA-G1
HLA-G
ILT-2
ILT-4
APC
Dendritic cell (myeloid)
HLA-G1
Trogocytosis?
IL-10
HLA-Gh
IL-10/HLA-G
tolerogenic loop
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cytokines
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IL-10HLA-G5
Induction of 
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sHLA-G
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FIGURE 3 | Human leukocyte antigen-G is a key mediator of the
tolerogenic loop arising from the crosstalk between immune cells in
the placenta. HLA-G promotes differentiation of DCs into tolerogenic
DCs secreting IL-10, TGF-β, and expressing HLA-G. IL-10 and TGF-β induce
Tregs. Tregs stimulate trophoblast cells to further upregulate expression
of HLA-G. HLA-G can be acquired by CD4+ T cells through trogocytosis,
increasing the pool of regulatory immune cells in the placenta. Cytotoxic
CD8+ T cells are inactivated and undergo apoptosis by binding of HLA-G
to the CD8 co-receptor. HLA-E presents HLA-G derived signal peptides
and bind to the CD94/NKG2A receptors on uterine NK cells inhibiting
cytotoxicity. Soluble HLA-G from trophoblast cells accumulates in
KIR2DL4+ endosomes in uterine NK cells, which may result in active
secretion of proangiogenic and proinflammatory cytokines, although this
is controversial.
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follicular fluid and in the genital tract (15, 54, 55). Furthermore,
HLA-G and sHLA-G has been detected in the male reproduc-
tive system and in semen (14, 56). After fertilization, HLA-G is
expressed by the blastocyst and the early embryo (57, 58). HLA-
G is also expressed at other immune privileged sites such as the
cornea and thymic epithelial cells (59, 60). Finally, sHLA-G can
be measured in peripheral blood from healthy female and male
donors, and during pregnancy the concentration raises two to five
times compared to what is observed in non-pregnant women (9,
12, 61, 62). One of the sources of soluble HLA-G5 in the blood
of non-pregnant women and in men is most likely monocytes;
though CD4+ and CD8+ T cells and B cells seem to be able to
secrete HLA-G5 as well, although in lower amounts (63). How-
ever, during pregnancy a substantial amount of sHLA-G may be
derived from the placenta by shed HLA-G1 and possibly secreted
HLA-G5. sHLA-G levels in blood are associated with HLA-G gene
polymorphisms and HLA-G haplotypes (19, 64).
The blastocyst implants into the uterine wall and the fetal-
derived extravillous trophoblast cells invade the decidua and are
involved in the remodeling of the spiral arteries. The maternal
blood flow and tissue leukocytes are hence in direct contact with
fetal trophoblast cells that express HLA-G (2, 65).
Still, it seems to be controversial, whether or not the solu-
ble HLA-G5 and -G6 isoforms are secreted by trophoblast cells
(66). Nonetheless, first trimester trophoblast expresses HLA-G5
and -G6 mRNA transcripts (28). One study has suggested that the
major sHLA-G isoform in maternal serum should be HLA-G6 (or
soluble HLA-G2) only consisting of heavy chains (67). However,
to our knowledge these results have not been reproduced.
REGULATION OF HLA-G EXPRESSION
The regulation of HLA-G expression has been studied on dif-
ferent levels, and the majority of studies have focused on the
importance of the genetic polymorphisms in the HLA-G gene as
previously mentioned. Especially the 14-bp ins/del polymorphism
in the 3′UTR, exon 8, of the HLA-G gene has been implicated in
mRNA stability and hence the overall HLA-G production. How-
ever, conflicting reports on whether the 14-bp-insertion allele is
associated with high or low level of expression of HLA-G exist.
Experiments with HLA-G transductants showed that K562 cells
with the 3′UTR 14 bp-insertion sequence had more stable mRNA
compared to transductants lacking the 14-bp insertion. The study
also looked at the functional impact of the 14-bp insertion on NK
cell cytotoxicity, and found that K562 transductant cells carry-
ing the 14-bp-insertion sequence were significantly less sensitive
to NK cell cytotoxicity as compared to K562 cells that did not
carry the 14-bp-insertion sequence (42). However, this study only
investigated the isolated role of the 14-bp sequence in experi-
ments performed with the use of a cell line, and the importance
of the 14-bp-insertion sequence may be modulated or influenced
by other linked polymorphisms in the 3′UTR, and in future stud-
ies it is important to study different HLA-G haplotypes. A study
by Martelli-Palomino et al. showed that the 14-bp deletion allele
correlated with higher blood plasma sHLA-G levels compared to
the 14-bp insertion in extended 3′UTR HLA-G haplotypes (47).
This is in line with previous studies, which have shown that the
14-bp ins/14 bp ins HLA-G genotype is associated with lower
blood plasma and serum sHLA-G levels, compared to the 14-
bp del/14 bp ins genotype and the 14-bp del/14 bp del genotype
(12, 13). MicroRNAs have also been shown to regulate HLA-G
expression and thereby function. In a study by Manaster et al.,
two microRNAs, miR-148a and miR-152 were shown to down-
regulate HLA-G expression and thereby reduce the binding of
HLA-G to its cognate inhibitory receptor immunoglobulin-like
transcript 2 (ILT-2). And interestingly, in the placenta, the cellu-
lar content of miR-148a and miR-152 shown to reduce HLA-G
expression was very low compared to other tissues. Therefore,
it can be speculated that this might be one of the reasons for
high tissue restricted expression in the placenta (45). The HLA-G
suppression by miR-152 in JEG-3 cells, followed by increased sus-
ceptibility to NK cell-mediated cytolysis, has also been shown in
a previous study (68). Soluble factors, like immune-modulatory
hormones and cytokines have shown to influence the transcrip-
tion of HLA-G. The rate of HLA-G transcription is increased
by the cytokine IFN-β. The indoleamine 2,3-dioxygenase (IDO),
which is an enzyme catabolizing tryptophan, has shown to increase
the shedding and expression of HLA-G in myeloid dendritic cells
(DCs), which contribute to a tolerogenic milieu (69). In fact, IDO
has shown to promote maternal tolerance toward the fetus by
catabolizing tryptophan and thereby suppressing the T cell activity
in mice (70).
The acquirement of HLA-G by HLA-G-negative cells has been
shown to be possible via trogocytosis. This mechanism is char-
acterized by the transfer of surface molecules from one cell to
another through cell–cell contact. Activated CD4+ and CD8+ T
cells can acquire HLA-G from antigen-presenting cells (APCs)
through this mechanism and thus contribute to an immune sup-
pressive milieu without expressing HLA-G themselves, but only
temporarily displaying it (71).
The trophoblast cells have an alternative HLA expression pro-
file compared to all other cells in the human body, in that they
only express the non-classical MHC class Ib (HLA-E, -F, and -G)
molecules, and to some extend the classical MHC class Ia HLA-
C. Usually, an altered HLA expression profile is associated with a
pathological condition, such as a virus infection or in malignant
transformation, and thus induces an immune response mediated
by the engagement and cytolytic killing of the cell in question by
NK cells. HLA-G, however, engages inhibitory molecules on leuko-
cytes rendering them anergic toward the trophoblast cells, thereby
protecting the allogeneic fetus (2, 65, 72). HLA-G interacts with
the ILT-2 and ILT-4 receptors, the co-receptor CD8, and maybe
the killer cell immunoglobulin-like receptor (KIR) 2DL4 (73).
THE HLA-G RECEPTORS
The uterine NK (uNK) cells, identified by being CD16−CD56bright,
as opposed to peripheral CD16+CD56+ NK cells, express
KIR2DL4, which is described as a receptor for HLA-G, although
a recent study has made this controversial (74, 75). KIR2DL4 has
an immunoreceptor tyrosine-based inhibitory motif (ITIM) at its
cytoplasmic tail, and is characterized by its expression in endo-
somes. Despite having an ITIM, KIR2DL4 when possibly bound
to HLA-G shows weak inhibition of uNK cell. Because of its
endosomal expression, at least in steady state conditions, KIR2DL4
seems to bind sHLA-G, which may activate the uNK cell to secrete
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cytokines and chemokines important for angiogenesis (76). How-
ever, further studies are certainly needed to clarify the possible
interactions between HLA-G and KIR2DL4.
Immunoglobulin-like transcript 2 and ILT-4 are inhibitory
receptors expressed on leukocytes. These receptors also bind other
HLA class I molecules, however, preferentially bind HLA-G (77).
ILT-2 and ILT-4 contain three ITIMs at their cytoplasmic tail. ILT-
2 (also named LILRB1) is expressed by monocytes, macrophages,
CD4+ and CD8+ T cells, B cells, and myeloid DCs and engages
only heterodimers of HLA-G1 or sHLA-G5 and β2m. ILT-4
(LILRB2) expressed by monocytes, macrophages, and myeloid
DCs can also interact with HLA-G monomers. The discrepancy
in HLA-G interaction with ILT-2 and ILT-4 has been clarified with
the use of crystal structures showing that ILT-2 cannot recognize
the β2m-free form of HLA-G, whereas ILT-4 preferably bind the
α3 domain of the HLA-G heavy chain (78). In fact, by binding to
its cognate inhibitory receptors, HLA-G has shown to up-regulate
the expression of ILT-2 and ILT-4. The functional consequence of
inhibitory receptor up-regulation by HLA-G was hypothesized to
be an increased sensitivity toward inhibition mediated, not only
by HLA-G, but also by classical HLA class I molecules known to
bind ILT-2 and ILT-4 (79). The co-receptor CD8 expressed on
cytotoxic T cells is also known to bind HLA-G. This interaction
causes apoptosis of the activated CD8+ T cells mediated by the
FAS ligand/FAS pathway (80).
HLA-G IN REPRODUCTIVE IMMUNOLOGY
Cell–cell interactions between leukocytes and trophoblast cells
mediated by HLA-G and its above-mentioned receptors are of
great interest in order to understand the immune regulation at
the feto-maternal interface (Figure 3). So far, several studies have
tried to elucidate the strict immune regulation taking place at this
anatomical site. A range of different studies indicate that HLA-
G might have a central position in the immune regulation at
conception and during pregnancy.
NK CELLS, DCs, AND T CELLS
It has become clear that DCs and T cells, especially Tregs, in the
decidua are important contributors to the tolerogenic milieu in
pregnancy and several studies have described such cells and their
implications in healthy and in complicated pregnancies. Some of
the described cell types have overlapping features. However, the
NK cells are by far the most abundant cells in the uterus.
The early decidua is characterized by an abundance of uter-
ine CD16−/dimCD56bright NK cells that are in close contact with
the fetal-derived extravillous trophoblast cells. uNK cells pos-
sess ILT-2, ILT-4, and KIR2DL4 receptors that bind HLA-G
expressed on the surface of the infiltrating trophoblast cells. The
CD16−/dimCD56bright NK cells are the largest population of lym-
phocytes in the uterus, they constitute 50–90% of lymphocytes in
human uterine decidua in early pregnancy. They are phenotypi-
cally and functionally distinct from conventional CD16+CD56dim
NK cells that circulate the periphery (81). They are recruited in
large numbers through the first and second trimester and par-
ticipate in the modification of the uterine spiral arteries, which
increases blood flow to the fetus (82). The crosstalk between DCs
and NK cells has been shown to be modulated by sHLA-G in cell
cultures. DCs cultured with sHLA-G showed a reduced ability to
induce NK cell activation (83). HLA-G non-amers have shown to
be presented by HLA-E, which stabilizes the HLA-E molecule (84).
Gregori et al. have shown that a specialized tolerogenic type
of DCs is accumulating in the human decidua during pregnancy.
These cells express HLA-G and are named DC-10 because they
secrete high amounts of IL-10. DC-10 can induce type 1 reg-
ulatory T (Tr1) cells, which are characterized by their cytokine
profile – secretion of IL-10 and TGF-β among others (73, 85).
Thymic stromal lymphopoietin (TSLP) is expressed by the
epithelial cells of Hassall’s corpuscles in the thymus and induce
DCs to stimulate Treg differentiation. During pregnancy though,
the function of the thymus is reduced, and the Treg expansion dur-
ing pregnancy has been proposed to take place in the placenta since
TSLP is produced by the trophoblast cells. The trophoblast cells
are in close contact with DCs around the spiral arteries and TSLP
likely activate the CD11+ DCs to secrete IL-10 and TGF-β and
instructing them to induce the differentiation of immature T cells
into CD4+CD25+FoxP3+ Tregs that also secrete IL-10 and TGF-β.
The Tregs further induce the trophoblast cells to express HLA-G,
which causes the decrease in uNK cytotoxicity. This tolerogenic
loop was recently described by Du et al. (86). The DCs in the study
by Du et al. secreted IL-10 as well as the HLA-G-expressing DC-10
described by Gregori et al. and it can be speculated if they might
be part of the same DC subset. Also, HLA-G presenting CD4+ T
cells have been identified at the feto-maternal interface, where they
may contribute to the tolerogenic milieu (87).
In mice, it has been shown that the overall CD4+CD25+ sup-
pressive T cell pool increases during pregnancy, that a third of the
CD4+CD25+ T cells in the pregnant uterus express FoxP3, and
that depletion of CD25+ T cells results in gestation failure (88).
HLA-G POLYMORPHISMS IN PRE-ECLAMPSIA AND
RECURRENT MISCARRIAGES
Pre-eclampsia is a multisystemic pregnancy disorder that is mani-
fested clinically in the late second and third trimester of pregnancy.
The etiology of pre-eclampsia is unknown, although a substan-
tial number of studies favor a theory based on a maladapted
immune system, with the more specific attributes of low levels of
immune regulatory cells and a low expression of HLA-G. The low
expression is hypothesized partly to be a consequence of genetic
variability. In support of this, a reduced level of HLA-G mRNA
is observed in pre-eclamptic placentas, which directly correlates
with the HLA-G genotype (5). Especially, the 14-bp ins/del 3′UTR
polymorphism in exon 8 has been extensively studied, and this
polymorphism has been found to be associated with severe pre-
eclampsia in several studies (5, 6, 8, 89, 90). However, some studies
have not observed an association between the 14-bp ins/del poly-
morphism and pre-eclampsia (91–93). Few studies address the
issue that pre-eclampsia presents in a mild and a severe form, and
furthermore, that it can be defined based on early- and late-onset,
and importantly, that these forms potentially have distinct etiolo-
gies (94). Other polymorphisms associated with pre-eclampsia are
typically present in the 5′URR and 3′UTR (8, 95).
HLA-G polymorphisms have been investigated in relation to
recurrent miscarriages, also, with contradicting results (64, 96,
97). Two meta-analysis have addressed the possible association
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between the 14-bp ins/del and recurrent miscarriages: the first per-
formed by Wang et al. including 14 studies, 1464 cases, and 1247
controls, found that the 14-bp ins/del is significantly associated
with unexplained recurrent miscarriage, and suggests that the 14-
bp-insertion increases the risk of recurrent miscarriage (98). These
findings were challenged by another meta-analysis performed by
Fan et al. including 17 studies, 1786 cases, and 1574 controls. The
authors concluded that the body of evidence to demonstrate a
conclusive association between the 14-bp ins/del with the risk of
recurrent miscarriages is inadequate (99). In a subgroup analysis,
however, they did find an association between the 14-bp ins/del
polymorphism and risk of recurrent miscarriage in women, who
suffered three or more miscarriages. Furthermore, they criticize
the meta-analysis by Wang et al. for including two different studies
based on the same study group (99).
An increasing amount of studies acknowledge that the etiol-
ogy of various pregnancy complications is based on the unique
immunogenetic combinations of the mother and the father. Pater-
nal immunogenetic factors may indeed contribute to the risk of
development of pre-eclampsia. One study shows that the pater-
nal HLA-G G*01:06 contribution significantly increases risk for
pre-eclampsia in multigravidas, who do not carry this allele (100).
REGULATORY IMMUNE CELLS IN PRE-ECLAMPSIA
Hsu et al. have recently published a study with the purpose of
describing the role of immune regulatory cells in pre-eclamptic
women (101). CD4+HLA-G+ T cells in the periphery and the
decidua from healthy pregnant women, and from pre-eclamptic
cases and non-pregnant women, were measured. In previous
studies, APCs characterized by being CD14+DC-SIGN+HLA-G+
and ILT-4+ have been described. These could be the same DCs
described by Gregori et al. (87). Like Tregs, this CD4+HLA-G+
T cell subset may play an important role in immune tolerance
during pregnancy. In the periphery, increase of CD4+HLA-G+
T cells during healthy pregnancies was observed compared to
non-pregnant controls. Pre-eclamptic women had a significantly
lower fraction of CD4+HLA-G+ T cells than healthy pregnant
women. CD4+HLA-G+ T cells seem to be more mature compared
to CD4+HLA-G− T cells because of their expression of CD80 and
CD86. Also, the CD4+HLA-G+ T cells expand in the decidua com-
pared to the periphery, but whether it is a local expansion of the T
cell pool or recruitment from the periphery is not known. Again,
pre-eclamptic women had a lower expansion of CD4+HLA-G+
T cells than healthy pregnant women. It was demonstrated that
the CD4+HLA-G+ T cells acquire their HLA-G by trogocytosis.
In this case from CD14+DC-SIGN+ DCs expressing HLA-G and
ILT-4 (101).
FUTURE ASPECTS AND CONCLUSION
As mentioned, HLA-G exists in a monomer form and a dimer
form, the latter by forming an intermolecular disulfide bridge
between two cysteine residues of the α1 domains of two HLA-
G molecules (102). Studies indicate that the dimer is the most
active form; it has a higher affinity than the monomer to ILT-2
and ILT-4, and the dimer enhances the ILT-2-mediated signal-
ing at the cellular level (103). In line with this, focus has been
drawn to HLA-G dimers and synthetic dimer HLA-G molecules
for possible therapeutic use (104). In mice, recombinant sHLA-G
and synthetic HLA-G molecules have been shown to inhibit the
early stages of arthritis in a rheumatoid arthritis disease model and
to significantly prolong the acceptance of skin grafts (104, 105).
It can be speculated that synthetic sHLA-G analogs might find a
place in the treatment of certain pregnancy-related disorders, such
as pre-eclampsia and assisted reproduction. However, a better fun-
damental understanding of the pathophysiology in these disorders
is needed before proceeding to such enterprises.
Also, in in vitro fertilization (IVF) treatments, the measure-
ment of sHLA-G in the embryo culture medium can be used as a
marker for improving successful assisted reproductive technology,
by choosing the fertilized oocytes with highest potential, as sHLA-
G positive culture medium correlates with pregnancy success (10,
58, 106).
In conclusion, for obtaining a successful conception and a preg-
nancy in terms of optimized immune modulation, a combined
expression of HLA-G from several sources seems to be important:
by the mother in the blood, in follicular fluid, and in the genital
tract, by the embryo and the trophoblast cells in the placenta, and
by the father through the presence of sHLA-G in semen. One of
our recent studies even revealed a significant association between
HLA-G genotype and the amount of sHLA-G in seminal plasma
(16). More studies are needed to elucidate the precise roles and
the importance of these different sources of HLA-G in relation
to uncomplicated pregnancies and in pre-eclampsia, in recurrent
miscarriage and in assisted reproduction, especially with respect to
the control of HLA-G expression involving HLA-G gene polymor-
phisms together with molecular and cellular immune interactions.
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